Assertio Therapeutics, Inc. (NasdaqGS:ASRT)’s Year Over Year Cash Flow Moves -1.00000

Assertio Therapeutics, Inc. (NasdaqGS:ASRT) has seen cash flow growth over the past year of -1.00000.  Cash flow and cash flow growth can reveal to an investor how quickly the firm is generating inflows of cash from their business operations.  

As we move deeper into earnings season, investors and analysts will be closely watching which companies look they are getting things right. Many investors will be following which companies beat or miss the estimates by a wide margin. Large surprise factors can cause a stock to jump or fall shortly after the actual numbers are released. Investors may also be tracking which industry leaders come out on top during the latest round of earnings reports. Tracking the sectors that are poised for growth may help give the investor a good idea for the types of stocks they may want to add to the portfolio as we get closer to the end of the current calendar year.

Assertio Therapeutics, Inc. (NasdaqGS:ASRT) of the Pharmaceuticals & Biotechnology sector closed the recent session at 4.030000 with a market value of $258984.

Taking look at some key returns data we can note the following:

Assertio Therapeutics, Inc. (NasdaqGS:ASRT) has Return on Invested Capital of 1.951776, with a 5-year average of 0.262345 and an ROIC quality score of 1.320287. Why is ROIC important to potential investors? It’s one of the most fundamental metrics in determining the value of a firm’s shares. It helps potential investors determine if the company is using it’s invested capital to return profits.

Drilling down into some additional key near-term indicators we note that the Capex to PPE ratio stands at 0.421540 for Assertio Therapeutics, Inc. (NasdaqGS:ASRT).  The Capex to PPE ratio shows you how capital intensive a company is. Stocks with an increasing (year over year) ratio may be moving to be more capital intensive and often underperform the market. Higher Capex also often means lower Free Cash Flow (Operating cash flow – Capex) generation and lower dividends as companies don’t have the cash to pay dividends if they are investing more in the business.

In addition to Capex to PPE we can look at Cash Flow to Capex.  This ration compares a stock’s operating cash flow to its capital expenditure and can identify if a firm can generate enough cash to meet investment needs.  Investors are looking for a ratio greater than one, which indicates that the firm can meet that need. Comparing to other firms in the same industry is relevant for this ratio. Assertio Therapeutics, Inc. (NasdaqGS:ASRT)’s Cash Flow to Capex stands at 13.164518.

Many investors enter the stock market without a plan in place. Investment goals may be a highly important part of coming out on top. Investors may need to set realistic and measureable goals in order to build a baseline for success. Defining investment goals clearly can help keep individual investors from making common mistakes and losing their shirts. Creating a plan for entering the equity market may start by setting up goals and outlining the objectives of the individual. These goals can differ depending on the person and situation. Many investors will opt to follow strategies put in place by others. This may work fine for some, but not as well for others. Keeping a close eye on particular stocks in the portfolio may help the investor when the time comes to adjust the holdings. Being able to adapt to rapidly changing market environments may turn out to be immensely important when the winds of uncertainty blow in.

Near-Term Growth Drilldown

Now we’ll take a look at some key growth data as decimals. One year cash flow growth ratio is calculated on a trailing 12 months basis and is a one year percentage growth of a firm’s cash flow from operations.  This number stands at -1.00000 for Assertio Therapeutics, Inc. (NasdaqGS:ASRT).  The one year Growth EBIT ratio stands at -6.47313 and is a calculation of one year growth in earnings before interest and taxes.  The one year EBITDA growth number stands at 0.83337 which is calculated similarly to EBIT Growth with just the addition of amortization.

Taking even a further look we note that the 1 year Free Cash Flow (FCF) Growth is at -1.00000.  The one year growth in Net Profit after Tax is -1.36009 and lastly sales growth was -0.18111.

In looking at some Debt ratios, Assertio Therapeutics, Inc. (NasdaqGS:ASRT) has a debt to equity ratio of 2.56930 and a Free Cash Flow to Debt ratio of 0.118335.  This ratio provides insight as to how high the firm’s total debt is compared to its free cash flow generated.  In terms of Net Debt to EBIT, that ratio stands at 7.14029.  This ratio reveals how easily a company is able to pay interest and capital on its net outstanding debt.  The lower the ratio the better as that indicates that the company is able to meet its interest and capital payments. Lastly we’ll take note of the Net Debt to Market Value ratio.  Assertio Therapeutics, Inc.’s ND to MV current stands at 1.757476. This ratio is calculated as follows: Net debt (Total debt minus Cash ) / Market value of the company.

Investing in the stock market may include having to keep emotions in check. When things get crazy, investors may be forced with tough decisions. Being able to stay away from impulsive decisions may help when the time comes to tweak the portfolio. Having the proper discipline and market perspective may also be a highly desirable trait for a successful trader. Investors who are able to practice discipline may be able to avoid emotional trading pitfalls in the future. Even highly experienced investors may have to someday make the difficult decisions in order to keep the portfolio strong. Figuring out what works and what doesn’t may take many years of trial and error. Learning to filter through the daily noise can be a big asset when trying to focus on the particularly important information.

50/200 Simple Moving Average Cross

Assertio Therapeutics, Inc. (NasdaqGS:ASRT) has a 0.74910 50/200 day moving average cross value. Cross SMA 50/200 (SMA = Simple Moving Average) and is calculated as follows:

Cross SMA 50/200 = 50 day moving average / 200day moving average. If the Cross SMA 50/200 value is greater than 1, it tell us that the 50 day moving average is above the 200 day moving average (golden cross), indicating an upward moving share price.

On the other hand if the Cross SMA 50/200 value is less than 1, this shows that the 50 day moving average is below the 200 day moving average (a death cross), and tells us that share prices has fallen recently and may continue to do so.

Individuals invest in order to get a return on the investment. Nobody enters the equity markets with the hope of losing money. Returns on investments may come in different forms. With any stock investment, there may be some level of risk involved. Understanding the risk is important and should be considered very carefully. Of course, the stock may go up and become a winner, or shares could sour and turn into losers. Returns in the stock market may often mimic the amount of risk. Generally speaking, the greater the risk, the greater the reward. With the greater chance of reward comes the greater chance of losses. Keeping a balanced and diversified portfolio can help manage the risk associated with investing in the stock market.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.